<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Pretreated PDX Models

The only PDX bank with over 60% of models derived from patients treated with the latest generation targeted cancer therapies

Leverage Pretreated PDX Models from Champions Oncology

Clinically Relevant Models

The largest living bank of pretreated PDX models, mirroring today's clinical trial population

Pretreated PDX Models

Established from cancer patients treated with the latest generation therapies

Multi-omic Characterization

Extensive clinical annotations coupled with multi-omic datasets and in vivo responses 

Industry's Most Extensive Collection of Biologically Relevant, Pretreated PDX Tumor Models

  • 700+ pretreated models across 53 cancer types
  • 80% of pretreated models are from advanced/metastatic tumors
  • Unique Model Cohorts: EGFRi, PARPi, KRASi, CDKi, BTKi, MEKi, METi, mTORi, CSF1Ri, BETi, CPi, RTKi and many more

Pretreated PDX Model Indications & Modalities

Colorectal
NSCLC/SCLC/ Lung
Sarcoma
Blood Cancer
Breast
Other Tumors
Ovarian
Head & Neck
Pancreatic
Melanoma
Esophageal
Gastric
GBM/Glioma
Prostate
Lymphoma
Bladder
RCC
Endometrial
Uterine
Hepatocellular
Chemotherapy
420
Combinatorial Chemotherapy
392
Small Molecule Inhibitor
241
Monoclonal Antibody
179
Checkpoint Inhibitor
63
Hormone Analogue
22
Receptor Modulator
18
Immunotherapy (Cellular)
12
Immunotherapy (General)
12
ADC
10
Immunotherapy (Vaccine)
7
Bispecific Antibody
2
Radiopharmaceutical
1

Available Curated Pretreated Model Cohorts

Breast Cancer Models:
  • HER2i Pretreated
  • CDK4/6i Pretreated ER+
Prostate Cancer Models:
  • Androgen Deprivation Therapy Resistant
Multi-Indication Models:
  • Osimertinib Pretreated EGFRm Models
  • Immune Therapy Pretreated Models
  • Immune Therapy Pretreated Resistant Models
  • PARPi Pretreated Models
  • Aromatase Inhibitor Resistant Models
  • Checkpoint Inhibitor (CPi) Immunotherapy Pretreated Models
  • Checkpoint Inhibitor (CPi) Immunotherapy Pretreated Resistant Models

Frequently Asked Questions

What are Pretreated PDX models ?
Pretreated PDX (Patient-Derived Xenograft) models are advanced research tools created by implanting human tumor tissue—previously exposed to specific cancer therapies and establishing them in animal models. This process allows researchers to study how tumors that have already been treated with drugs behave and evolve, including their mechanisms of resistance to those treatments. By mimicking real-world patient scenarios, pretreated PDX models offer valuable insights into the efficacy and resistance patterns of new anticancer therapies, enhancing the development of more effective treatments and minimizing risks in clinical trials.
What are the advantages of Champions' pretreated PDX models ?

Evaluating novel cancer therapies using Champion's biobank of pretreated PDX models offers several benefits, including:

Study Drug Resistance Mechanisms: A robust bank of 700+ pretreated models to investigate how tumors develop resistance to current treatments and identify new targets or strategies to counteract this resistance.

Evaluate Therapeutic Efficacy: Evaluate therapeutic efficacy of your novel therapies by testing them on a bank of pretreated models exposed to the latest therapies such as small molecule inhibitors, chemotherapy, antibodies, immunotherapeutics, and more.

Optimizing your pipeline and discovering new targets: Using pretreated PDX models helps optimize your test agents by understanding molecular interactions between the current line of treatments and cancers and identifying new drug targets, paving the way for more effective second- and third-line therapies.

Reducing Drug Development Costs: Utilizing pretreated PDX models in early drug testing can lower cancer drug development expenses by eliminating ineffective compounds before advancing to costly human clinical trials.

How do I find the most suitable pretreated PDX model for my research ?

You can access Champions’ database for model selection in Lumin:

Navigate to Lumin.bio and request access to Lumin Analytics.

There, you can use Model Select to search our database filtering for the tumor type and pretreatment of your need. You can also filter for in vivo response, molecular characteristics, and patient profile, to make your model selection the most precise and your studies the most successful. 

Request Access to Lumin Analytics to Select Pretreated PDX Models